Repository logo
 
Publication

Vaccine effectiveness against influenza A(H3N2) and B among laboratory‐confirmed, hospitalised older adults, Europe, 2017‐18: A season of B lineage mismatched to the trivalent vaccine

2020-05Journal article Open access
Simple item page
dc.contributor.authorRose, Angela M.C.
dc.contributor.authorKissling, Esther
dc.contributor.authorGherasim, Alin
dc.contributor.authorCasado, Itziar
dc.contributor.authorBella, Antonino
dc.contributor.authorLaunay, Odile
dc.contributor.authorLazăr, Mihaela
dc.contributor.authorMarbus, Sierk
dc.contributor.authorKuliese, Monika
dc.contributor.authorSyrjänen, Ritva
dc.contributor.authorMachado, Ausenda
dc.contributor.authorKurečić Filipović, Sanja
dc.contributor.authorLarrauri, Amparo
dc.contributor.authorCastilla, Jesús
dc.contributor.authorAlfonsi, Valeria
dc.contributor.authorGaltier, Florence
dc.contributor.authorIvanciuc, Alina
dc.contributor.authorMeijer, Adam
dc.contributor.authorMickiene, Aukse
dc.contributor.authorIkonen, Niina
dc.contributor.authorGómez, Verónica
dc.contributor.authorLovrić Makarić, Zvjezdana
dc.contributor.authorMoren, Alain
dc.contributor.authorValenciano, Marta
dc.contributor.authorI-MOVE Hospital study team
dc.date.accessioned2021-04-05T17:38:11Z
dc.date.available2021-04-05T17:38:11Z
dc.date.issued2020-05
dc.description.abstractBackground: Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2017-18, predominated by influenza B. WHO-recommended, trivalent vaccine components were lineage-mismatched for B. The I-MOVE hospital network measured 2017-18 seasonal influenza vaccine effectiveness (IVE) against influenza A(H3N2) and B among hospitalised patients (≥65 years) in Europe. Methods: Following the same generic protocol for test-negative design, hospital teams in nine countries swabbed patients ≥65 years with recent onset (≤7 days) severe acute respiratory infection (SARI), collecting information on demographics, vaccination status and underlying conditions. Cases were RT-PCR positive for influenza A(H3N2) or B; controls: negative for any influenza. "Vaccinated" patients had SARI onset >14 days after vaccination. We measured pooled IVE against influenza, adjusted for study site, age, sex, onset date and chronic conditions. Results: We included 3483 patients: 376 influenza A(H3N2) and 928 B cases, and 2028 controls. Most (>99%) vaccinated patients received the B lineage-mismatched trivalent vaccine. IVE against influenza A(H3N2) was 24% (95% CI: 2 to 40); 35% (95% CI: 6 to 55) in 65- to 79-year-olds and 14% (95% CI: -22 to 39) in ≥80-year-olds. Against influenza B, IVE was 30% (95% CI: 16 to 41); 37% (95% CI: 19 to 51) in 65- to 79-year-olds and 19% (95% CI: -7 to 38) in ≥80-year-olds. Conclusions: IVE against influenza B was similar to A(H3N2) in hospitalised older adults, despite trivalent vaccine and circulating B lineage mismatch, suggesting some cross-protection. IVE was lower in those ≥80 than 65-79 years. We reinforce the importance of influenza vaccination in older adults as, even with a poorly matched vaccine, it still protects one in three to four of this population from severe influenza.pt_PT
dc.description.sponsorshipHorizon 2020 Framework Programme, Grant/Award Number: 634446pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationInfluenza Other Respir Viruses. 2020 May;14(3):302-310. doi: 10.1111/irv.12714. Epub 2020 Feb 5.pt_PT
dc.identifier.doi10.1111/irv.12714pt_PT
dc.identifier.issn1750-2640
dc.identifier.urihttp://hdl.handle.net/10400.18/7643
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWiley Open Accesspt_PT
dc.relationI-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/full/10.1111/irv.12714pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectAgedpt_PT
dc.subjectAged, 80 and overpt_PT
dc.subjectCase-Control Studiespt_PT
dc.subjectCross Protectionpt_PT
dc.subjectEuropept_PT
dc.subjectFemalept_PT
dc.subjectHospitalizationpt_PT
dc.subjectHumanspt_PT
dc.subjectInfluenza A Virus, H3N2 Subtypept_PT
dc.subjectInfluenza B viruspt_PT
dc.subjectInfluenza Vaccinespt_PT
dc.subjectInfluenza, Humanpt_PT
dc.subjectMalept_PT
dc.subjectRespiratory Tract Infectionspt_PT
dc.subjectSeasonspt_PT
dc.subjectVaccine Potencypt_PT
dc.subjectDeterminantes da Saúde e da Doençapt_PT
dc.subjectInfecções Respiratóriaspt_PT
dc.titleVaccine effectiveness against influenza A(H3N2) and B among laboratory‐confirmed, hospitalised older adults, Europe, 2017‐18: A season of B lineage mismatched to the trivalent vaccinept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleI-MOVE+ Integrated Monitoring of Vaccines Effects in Europe: a platform to measure and compare effectiveness and impact of influenza and pneumococcal vaccines and vaccination strategies in the elderly
oaire.awardURIinfo:eu-repo/grantAgreement/EC/H2020/634446/EU
oaire.citation.endPage310pt_PT
oaire.citation.issue3pt_PT
oaire.citation.startPage302pt_PT
oaire.citation.titleInfluenza and Other Respiratory Virusespt_PT
oaire.citation.volume14pt_PT
oaire.fundingStreamH2020
project.funder.identifierhttp://doi.org/10.13039/501100008530
project.funder.nameEuropean Commission
rcaap.embargofctAcesso de acordo com política editorial da revista.pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isProjectOfPublicationccfd73a6-6f3c-4702-956c-544973bca97d
relation.isProjectOfPublication.latestForDiscoveryccfd73a6-6f3c-4702-956c-544973bca97d

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
39_Vaccine effectiveness.pdf
Size:
397.98 KB
Format:
Adobe Portable Document Format
Download

Collections

DEP - Artigos em revistas internacionais